Severe dyslipidemia title: known by patients, but is it treated?

Le résumé fourni par la source

Abstract Funding Acknowledgements Type of funding sources: None. Introduction Patients with severe dyslipidemia (> 190 mg / dl) are considered in the clinical practice guidelines of high cardiovascular risk, therefore, diagnosis and treatment is essential, as well as the rest of the CV risk factors. But real-life records give us data of lack of control, justified by lack of adherence to treatment, underdiagnosis and therapeutic inertia among other factors. The aim of our work was to analyze patients knowledge about their dyslipidemia, treatment and the impact on their cardiovascular health. Materials and methods Patients with severe dyslipidemia (>190 mg/dl) from the familial hypercholesterolemia screening program were analyzed consecutively from February 1 – September 30, 2022. It was performed from Clinical Analysis, with an alarm system to detect severe dyslipidemia in people over 18 years of age in coordination with the Cardiovascular Prevention Unit of Cardiology and Genetics. All patients underwent a health questionnaire. Results n = 353. Mean age 52.2 years. 51.6% women (Table 1 baseline characteristics). 86.5% knew that they had dyslipidemia problems, mainly non-DM (85% vs 68%; p0.009), with familiy history (FH) of dyslipidemia (90% vs 81%;p 0.027) and older people (53.7 vs 47.1 years; p.001) But only 14.4% took treatment, patients with DM (31% vs. 13%; p0016), with FH of LDLhigh children (31% vs 12%; p 0.02), with personal history of CV disease (37% vs 13%; p 0.007) and BMI > 30 (20% vs 11%; p 0.017). 53.4% had taken treatment at some time, patients with hypertension (67% vs 49%;p 0.01), with family history of dyslipidemia (59% vs 44%; p 0.005), personal history of CV disease (87% vs 51%; p 0.005) and those over 40 years (55% vs 36%; p 0.016) 91.4% recognized the impact of dyslipidemia on the prognosis CV, mainly those with family history of dyslipidemia (94% vs 86%; p.017) and those under 40 years (100% vs 90.7%; p0.04). Conclusions A high percentage of patients recognize their dyslipidemia problem and the possible impact on their health, but less than 15% take lipid-lowering treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.